Home/Pipeline/iT Cell Programs

iT Cell Programs

Solid Tumors

Discovery/PreclinicalResearch

Key Facts

Indication

Solid Tumors

Phase

Discovery/Preclinical

Status

Research

Company

Century Therapeutics

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company developing allogeneic, iPSC-derived cell therapies for oncology and autoimmunity. Its core strategy is to utilize a renewable master iPSC bank, combined with precision genetic engineering, to create standardized, scalable, and readily available therapeutic products. Key achievements include advancing its lead CNTY-101 program into Phase 1 trials for B-cell malignancies and securing strategic collaborations with Bristol Myers Squibb and Bayer. The company's long-term vision is to establish iPSC-derived cell therapies as a mainstream, accessible treatment modality.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed